The JAK2 46/1 haplotype influences PD-L1 expression

Area of Science:

• Genetics and Immunology
• Hematology
• Molecular Biology

Background:

• The JAK2 46/1 haplotype is a known risk factor for myeloproliferative neoplasms (MPNs), but the underlying mechanism remains unclear.
• Inflammation and immune responses are implicated in MPN pathogenesis, suggesting a potential role for immune-related pathways in the 46/1 haplotype's effect.

Purpose of the Study:

• To investigate the mechanism by which the JAK2 46/1 haplotype increases MPN risk.
• To explore the role of programmed death-1 receptor ligand (PD-L1) in the context of the JAK2 46/1 haplotype and MPN development.

Main Methods:

• Analysis of PD-L1 expression in healthy carriers of the 46/1 haplotype and in patients with MPN.
• Circular chromosome conformation capture (4C) to assess physical interactions between PD-L1, PD-L2, and JAK2 loci.
• CRISPR/Cas9 genome editing to identify regulatory regions within JAK2 intron 2.

Main Results:

• Elevated PD-L1 expression was observed in individuals with the 46/1 haplotype and in CD34+ cells from MPN patients.
• 4C revealed distinct physical interactions between PD-L1/PD-L2 and JAK2 in 46/1 versus non-risk haplotypes.
• A specific region in JAK2 intron 2 was identified as influencing both JAK2 and PD-L1 expression.

Conclusions:

• Increased PD-L1 expression associated with the JAK2 46/1 haplotype may contribute to the inherited risk of MPNs.
• The findings highlight a potential link between immune regulation (PD-L1) and genetic predisposition (JAK2 46/1 haplotype) in MPN development.